Corrections
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol
2014; 15: 1324 2015; 16: 324
Ndiaye C, Mena M, Alemany L, et al.
HPV DNA, E6/E7 mRNA, and p16INK4a
detection in head and neck cancers: a
systematic review and meta-analysis.
Lancet Oncol 2014; 15: 1319–31—In
figure 3 of the Article, the prevalence
of HPV type 18 in oral cavity in Africa
should read 1·8%, and in oropharynx
in Oceania HPV type 18 should appear
as the second most common type after
16, and before 35, with a prevalence
of 1·7%. Data for HPV type 53 should
not have appeared in this graph. These
corrections have been made to the
online version as of May 28, 2015.
Correction to Lancet Oncol
2015; 16: 522–30
Eggermont AMM, Chiarion-Sileni V,
Grob J-J, et al. Adjuvant ipilimumab
versus placebo after complete resection
of high-risk stage III melanoma (EORTC
18071): a randomised, double-blind,
phase 3 trial. Lancet Oncol 2015;
16: 522–30—The webappendix for
this Article has been corrected as of
May 28, 2015.
www.thelancet.com/oncology Vol 16 June 2015
2015; 16: 499–508
Zapatero A, Guerrero A, Maldonado X,
et al. High-dose radiotherapy with short-
term or long-term androgen deprivation
in localised prostate cancer (DART01/05
GICOR): a randomised, controlled,
phase 3 trial. Lancet Oncol 2015;
16: 320–27—The title of table 2 in this
Article should read “Univariate and
multivariate analysis of biochemical
progression-free survival”. In the fifth
paragraph in the Results section, the
number of patients in the short-term
group who died of cancer, but not of
the prostate, should read 14 (8%)
and the number in the long-term
group should read three (2%). These
corrections have been made online as
of May 28, 2015.
Tabernero J, Takayuki Y, Cohn AL,
et al. Ramucirumab versus placebo
in combination with second-line
FOLFIRI in patients with metastatic
colorectal carcinoma that progressed
during or after first-line therapy with
bevacizumab, oxaliplatin, and a
fluoropyrimidine (RAISE): a randomised,
double-blind, multicentre, phase 3 study.
Lancet Oncol 2015; 16: 499–508—In
table 1 of this Article, the proportion
of patients with two metastatic sites
in the ramucirumab group should
read 38%. In figure 2, panel B, the log-
rank p value should read p=0·0005.
In table 2, the proportion of patients
with grade 3 thrombocytopenia in the
ramucirumab group should read 3%.
These corrections have been made to
the online version as of May 28, 2015.
e262